Real-Life Data on the Efficacy of Canakinumab in Patients with Adult-Onset Still’s Disease
Background. Interleukin-1 inhibition has revealed to be a successful treatment approach for patients with adult-onset Still’s disease (AOSD). However, real-life experience is focused on the use of anakinra, while data about canakinumab (CAN) are mainly based on case reports and small case series. Pa...
Saved in:
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2020-01-01
|
| Series: | Mediators of Inflammation |
| Online Access: | http://dx.doi.org/10.1155/2020/8054961 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832563329542914048 |
|---|---|
| author | Antonio Vitale Virginia Berlengiero Jurgen Sota Luisa Ciarcia Nicola Ricco Sara Barneschi Mariam Mourabi Giuseppe Lopalco Chiara Marzo Francesca Bellisai Florenzo Iannone Bruno Frediani Luca Cantarini |
| author_facet | Antonio Vitale Virginia Berlengiero Jurgen Sota Luisa Ciarcia Nicola Ricco Sara Barneschi Mariam Mourabi Giuseppe Lopalco Chiara Marzo Francesca Bellisai Florenzo Iannone Bruno Frediani Luca Cantarini |
| author_sort | Antonio Vitale |
| collection | DOAJ |
| description | Background. Interleukin-1 inhibition has revealed to be a successful treatment approach for patients with adult-onset Still’s disease (AOSD). However, real-life experience is focused on the use of anakinra, while data about canakinumab (CAN) are mainly based on case reports and small case series. Patients and Methods. Patients classified with AOSD according to Yamaguchi criteria and treated with CAN were consecutively enrolled. Their clinical and therapeutic data were retrospectively collected and statistically analysed to assess the role of CAN as a therapeutic opportunity in AOSD patients in terms of clinical and laboratory disease control along with corticosteroid-sparing effect. Results. Nine AOSD patients (8 females and 1 male) treated with CAN for 15.00±12.3 months were enrolled. Resolution of clinical manifestations was reported in 8/9 cases at the 3-month assessment; a significant decrease in the number of tender joints (p=0.009), swollen joints (p=0.027), and disease activity score on 28 joints-C-reactive protein (DAS28-CRP) (p=0.044) was observed during the study period. The systemic score of disease activity significantly decreased at the 3-month and 6-month assessments and at the last visit compared to the start of treatment (p=0.028, p=0.028, and p=0.018, respectively). The daily corticosteroid dosage was significantly reduced at the 3-month and at the last follow-up visits (p=0.017 and p=0.018, respectively). None of the patients experienced adverse events or severe adverse events during the follow-up. Conclusions. CAN has shown prompt and remarkable effectiveness in controlling AOSD activity in a real-life contest, with a significant glucocorticoid-sparing effect and an excellent safety profile. |
| format | Article |
| id | doaj-art-f83a1f5afdca44e280abe8893a737ffb |
| institution | Kabale University |
| issn | 0962-9351 1466-1861 |
| language | English |
| publishDate | 2020-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Mediators of Inflammation |
| spelling | doaj-art-f83a1f5afdca44e280abe8893a737ffb2025-02-03T01:20:30ZengWileyMediators of Inflammation0962-93511466-18612020-01-01202010.1155/2020/80549618054961Real-Life Data on the Efficacy of Canakinumab in Patients with Adult-Onset Still’s DiseaseAntonio Vitale0Virginia Berlengiero1Jurgen Sota2Luisa Ciarcia3Nicola Ricco4Sara Barneschi5Mariam Mourabi6Giuseppe Lopalco7Chiara Marzo8Francesca Bellisai9Florenzo Iannone10Bruno Frediani11Luca Cantarini12Research Center of Systemic Autoinflammatory Diseases, Behçet’s Disease and Rheumatology-Ophthalmology Collaborative Uveitis Center, Rheumatology Unit, Department of Medical Sciences, Surgery and Neurosciences, University of Siena, Siena, ItalyResearch Center of Systemic Autoinflammatory Diseases, Behçet’s Disease and Rheumatology-Ophthalmology Collaborative Uveitis Center, Rheumatology Unit, Department of Medical Sciences, Surgery and Neurosciences, University of Siena, Siena, ItalyResearch Center of Systemic Autoinflammatory Diseases, Behçet’s Disease and Rheumatology-Ophthalmology Collaborative Uveitis Center, Rheumatology Unit, Department of Medical Sciences, Surgery and Neurosciences, University of Siena, Siena, ItalyResearch Center of Systemic Autoinflammatory Diseases, Behçet’s Disease and Rheumatology-Ophthalmology Collaborative Uveitis Center, Rheumatology Unit, Department of Medical Sciences, Surgery and Neurosciences, University of Siena, Siena, ItalyResearch Center of Systemic Autoinflammatory Diseases, Behçet’s Disease and Rheumatology-Ophthalmology Collaborative Uveitis Center, Rheumatology Unit, Department of Medical Sciences, Surgery and Neurosciences, University of Siena, Siena, ItalyResearch Center of Systemic Autoinflammatory Diseases, Behçet’s Disease and Rheumatology-Ophthalmology Collaborative Uveitis Center, Rheumatology Unit, Department of Medical Sciences, Surgery and Neurosciences, University of Siena, Siena, ItalyResearch Center of Systemic Autoinflammatory Diseases, Behçet’s Disease and Rheumatology-Ophthalmology Collaborative Uveitis Center, Rheumatology Unit, Department of Medical Sciences, Surgery and Neurosciences, University of Siena, Siena, ItalyRheumatology Unit, Department of Emergency and Organ Transplantation, University of Bari, Bari, ItalyResearch Center of Systemic Autoinflammatory Diseases, Behçet’s Disease and Rheumatology-Ophthalmology Collaborative Uveitis Center, Rheumatology Unit, Department of Medical Sciences, Surgery and Neurosciences, University of Siena, Siena, ItalyResearch Center of Systemic Autoinflammatory Diseases, Behçet’s Disease and Rheumatology-Ophthalmology Collaborative Uveitis Center, Rheumatology Unit, Department of Medical Sciences, Surgery and Neurosciences, University of Siena, Siena, ItalyRheumatology Unit, Department of Emergency and Organ Transplantation, University of Bari, Bari, ItalyResearch Center of Systemic Autoinflammatory Diseases, Behçet’s Disease and Rheumatology-Ophthalmology Collaborative Uveitis Center, Rheumatology Unit, Department of Medical Sciences, Surgery and Neurosciences, University of Siena, Siena, ItalyResearch Center of Systemic Autoinflammatory Diseases, Behçet’s Disease and Rheumatology-Ophthalmology Collaborative Uveitis Center, Rheumatology Unit, Department of Medical Sciences, Surgery and Neurosciences, University of Siena, Siena, ItalyBackground. Interleukin-1 inhibition has revealed to be a successful treatment approach for patients with adult-onset Still’s disease (AOSD). However, real-life experience is focused on the use of anakinra, while data about canakinumab (CAN) are mainly based on case reports and small case series. Patients and Methods. Patients classified with AOSD according to Yamaguchi criteria and treated with CAN were consecutively enrolled. Their clinical and therapeutic data were retrospectively collected and statistically analysed to assess the role of CAN as a therapeutic opportunity in AOSD patients in terms of clinical and laboratory disease control along with corticosteroid-sparing effect. Results. Nine AOSD patients (8 females and 1 male) treated with CAN for 15.00±12.3 months were enrolled. Resolution of clinical manifestations was reported in 8/9 cases at the 3-month assessment; a significant decrease in the number of tender joints (p=0.009), swollen joints (p=0.027), and disease activity score on 28 joints-C-reactive protein (DAS28-CRP) (p=0.044) was observed during the study period. The systemic score of disease activity significantly decreased at the 3-month and 6-month assessments and at the last visit compared to the start of treatment (p=0.028, p=0.028, and p=0.018, respectively). The daily corticosteroid dosage was significantly reduced at the 3-month and at the last follow-up visits (p=0.017 and p=0.018, respectively). None of the patients experienced adverse events or severe adverse events during the follow-up. Conclusions. CAN has shown prompt and remarkable effectiveness in controlling AOSD activity in a real-life contest, with a significant glucocorticoid-sparing effect and an excellent safety profile.http://dx.doi.org/10.1155/2020/8054961 |
| spellingShingle | Antonio Vitale Virginia Berlengiero Jurgen Sota Luisa Ciarcia Nicola Ricco Sara Barneschi Mariam Mourabi Giuseppe Lopalco Chiara Marzo Francesca Bellisai Florenzo Iannone Bruno Frediani Luca Cantarini Real-Life Data on the Efficacy of Canakinumab in Patients with Adult-Onset Still’s Disease Mediators of Inflammation |
| title | Real-Life Data on the Efficacy of Canakinumab in Patients with Adult-Onset Still’s Disease |
| title_full | Real-Life Data on the Efficacy of Canakinumab in Patients with Adult-Onset Still’s Disease |
| title_fullStr | Real-Life Data on the Efficacy of Canakinumab in Patients with Adult-Onset Still’s Disease |
| title_full_unstemmed | Real-Life Data on the Efficacy of Canakinumab in Patients with Adult-Onset Still’s Disease |
| title_short | Real-Life Data on the Efficacy of Canakinumab in Patients with Adult-Onset Still’s Disease |
| title_sort | real life data on the efficacy of canakinumab in patients with adult onset still s disease |
| url | http://dx.doi.org/10.1155/2020/8054961 |
| work_keys_str_mv | AT antoniovitale reallifedataontheefficacyofcanakinumabinpatientswithadultonsetstillsdisease AT virginiaberlengiero reallifedataontheefficacyofcanakinumabinpatientswithadultonsetstillsdisease AT jurgensota reallifedataontheefficacyofcanakinumabinpatientswithadultonsetstillsdisease AT luisaciarcia reallifedataontheefficacyofcanakinumabinpatientswithadultonsetstillsdisease AT nicolaricco reallifedataontheefficacyofcanakinumabinpatientswithadultonsetstillsdisease AT sarabarneschi reallifedataontheefficacyofcanakinumabinpatientswithadultonsetstillsdisease AT mariammourabi reallifedataontheefficacyofcanakinumabinpatientswithadultonsetstillsdisease AT giuseppelopalco reallifedataontheefficacyofcanakinumabinpatientswithadultonsetstillsdisease AT chiaramarzo reallifedataontheefficacyofcanakinumabinpatientswithadultonsetstillsdisease AT francescabellisai reallifedataontheefficacyofcanakinumabinpatientswithadultonsetstillsdisease AT florenzoiannone reallifedataontheefficacyofcanakinumabinpatientswithadultonsetstillsdisease AT brunofrediani reallifedataontheefficacyofcanakinumabinpatientswithadultonsetstillsdisease AT lucacantarini reallifedataontheefficacyofcanakinumabinpatientswithadultonsetstillsdisease |